Korean company’s Alzheimer’s disease treatment concludes phase II trials

Korean biotechnology company AriBio Co Ltd’s new drug to treat Alzheimer’s disease has completed phase II trials. The results show that the drug, AR1001, acts against the protein which forms amyloid plaques that can disrupt healthy cell functioning in Alzheimer’s.

Early analysis also suggests that the drug inhibits neuron cell death and restores the ability to strengthen connections between neurons.

The trials consisted of 210 participants and results are expected to be published in early 2021.

Click here to read more.

AKBC Membership

AKBC welcomes new members from both the Australian and Korean business community.

Join now

What’s on

AKBC runs events on a regular basis to keep members informed about the latest developments in Australia-Korea trade and investment.

See events

AKBC Newsletter

AKBC issues a monthly newsletter about the latest trends and developments in the Australia-Korea relationship. Sign up to our free e-newsletter by entering your email below.

Australia Korea Business Council
PO Box 24430
Melbourne, Vic 3001 Australia
Liz Griffin – Executive Director

The Australia-Korea Business Council is the leading national body committed to strengthening the Australia-Korea economic relationship.